Improving Individualized Care in Advanced and Metastatic Bladder Cancer

Improving Individualized Care in Advanced and Metastatic Bladder Cancer

As the therapeutic landscape for advanced and metastatic urothelial carcinoma (mUC) rapidly evolves, staying updated on the latest guidelines, new approvals, and clinical data is crucial for optimizing patient outcomes. In this on-demand video featuring experts in bladder cancer, tune in for a discussion on differentiating treatment options based on the latest efficacy and safety data, and strategies to individualize treatment plans, manage adverse events, and improve patient adherence to therapies. Real-world case discussions will highlight how to align guideline-based recommendations with patient goals and preferences, and enhance collaborative, shared decision-making for improved patient-centered care. This activity is delivered in partnership with Cancer Care.

  • Provider:PRIME Education, Inc. (PRIME®)
  • Activity Link: https://primeinc.org/online/improving-individualized-care-advanced-metastatic-bladder-cancer
  • Start Date: 2024-11-04 06:00:00
  • End Date: 2024-11-04 06:00:00
  • Credit Details: AAPA Category 1 Credit™️: 1.0 hours
    AMA PRA Category 1 Credit™️: 1.0 hours
    Nursing: 1.0 hours
    Pharmacy: 1.0 hours
  • MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: Source: Gilead Sciences, Inc. - Amount: 36250.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Medical Oncology
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.